You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Patent: 8,377,690


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,377,690
Title:Cells and methods for producing blocking antibodies to human RANKL
Abstract: Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.
Inventor(s): Anderson; Dirk M (Port Townsend, WA)
Assignee: Immunex Corporation (Thousand Oaks, CA)
Application Number:12/802,801
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 8,377,690

Introduction

United States Patent 8,377,690, like any other patent, is a complex document that requires a thorough analysis to understand its claims, implications, and position within the broader patent landscape. This analysis will delve into the key aspects of the patent, including its claims, inventorship, and the strategic and legal contexts in which it operates.

Understanding the Patent Claims

To analyze the claims of a patent like 8,377,690, it is crucial to identify the "true and only" inventors and the scope of the invention as defined by the patent claims. According to U.S. patent law, the inventor is the person who conceives the subject matter of at least one claim of the patent[4].

Conception and Reduction to Practice

The conception of an idea is a critical step in determining inventorship. It involves the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention. This idea must be sufficiently definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation[4].

Claim Analysis

Each claim in the patent must be analyzed to determine the exact subject matter of the invention. This involves identifying the features of the invention that are claimed and verifying which individuals conceived these features. The claims should be clear, concise, and definite to avoid ambiguity and potential legal challenges.

Inventorship and Its Implications

Inventorship is a pivotal aspect of patent law. Incorrect or incomplete identification of inventors can lead to the patent being invalid and unenforceable. Here are some key points to consider:

True and Only Inventors

Only those who conceived the subject matter of at least one claim of the patent should be listed as inventors. Contributions such as reducing the invention to practice or performing experiments do not qualify someone as an inventor unless they also conceived part of the invention[4].

Deceptive Intent

Any deceptive intent in naming inventors can render the patent unenforceable, even if the correct inventorship can be established later. This underscores the importance of accurate and honest disclosure of inventorship information[4].

Patent Landscape and Competitive Analysis

Understanding the patent landscape involves analyzing the broader context in which the patent operates, including competitors, technological trends, and legal challenges.

Competitive Intelligence

Tools like LexisNexis PatentSight+ can be invaluable in this analysis. They provide contextualized and evidence-based IP insights, enabling companies to assess the value or risk of acquisition candidates, optimize portfolios, and identify key patents and licensing opportunities[2].

Portfolio PAEs and Litigation PAEs

The landscape also includes Patent Assertion Entities (PAEs), which can significantly impact the patent ecosystem. PAEs can be categorized into Portfolio PAEs and Litigation PAEs, each with distinct business models. Portfolio PAEs negotiate licenses covering large portfolios without initial litigation, while Litigation PAEs focus on filing lawsuits to enforce their patents[3].

Strategic Decision-Making

For companies holding or considering acquiring patents like 8,377,690, strategic decision-making is crucial.

Patent Value Indicators

Using metrics like the Patent Asset Index, companies can assess the quality and impact of their patent portfolios. This helps in making informed decisions about licensing, litigation, and portfolio optimization[2].

Visualization and Communication

Effective visualization tools can help communicate the value of IP to the business, elevating IP awareness and storytelling. This is particularly important for turning the patent department from a cost center into a profit center[2].

Legal Considerations

The legal context is vital when analyzing a patent.

National Phase Entry

For patents entering the national phase in the U.S., the use of Form PTO-1390 is recommended to ensure proper processing. This form helps in identifying the submission as a national phase entry and provides a checklist of required items[1].

Litigation and Enforcement

Patent litigation can be a significant aspect of enforcing patent rights. Understanding the litigation behavior of PAEs and other entities can help in preparing for potential legal challenges. For instance, Litigation PAEs file a high percentage of patent lawsuits, and most of these cases settle within a year[3].

Case Study: Wireless Chipset Sector

A case study on the wireless chipset sector, as conducted by the FTC, highlights the complexities of patent assertion. PAEs in this sector often target a broad range of industries, including retail trade, and their activities can have significant economic implications. This study underscores the need for thorough analysis and strategic planning in managing patent portfolios[3].

Key Takeaways

  • Accurate Inventorship: Correct identification of inventors is crucial for the validity and enforceability of a patent.
  • Claim Analysis: Each claim must be clearly defined to avoid legal challenges.
  • Competitive Intelligence: Tools like PatentSight+ are essential for understanding the patent landscape and making strategic decisions.
  • PAE Activity: Understanding the business models of PAEs can help in navigating the patent ecosystem.
  • Legal Compliance: Proper use of forms like PTO-1390 and awareness of national phase entry requirements are necessary for smooth patent processing.
  • Litigation Preparedness: Knowing the litigation behavior of PAEs and other entities can help in preparing for legal challenges.

FAQs

Q: What is the importance of accurate inventorship in a patent application? A: Accurate inventorship is crucial because incorrect or incomplete identification of inventors can render the patent invalid and unenforceable.

Q: How do Portfolio PAEs and Litigation PAEs differ in their business models? A: Portfolio PAEs negotiate licenses covering large portfolios without initial litigation, while Litigation PAEs focus on filing lawsuits to enforce their patents.

Q: What is the role of tools like LexisNexis PatentSight+ in patent analysis? A: These tools provide contextualized and evidence-based IP insights, enabling companies to assess the value or risk of acquisition candidates, optimize portfolios, and identify key patents and licensing opportunities.

Q: Why is it important to use Form PTO-1390 for national phase entry in the U.S.? A: Using Form PTO-1390 ensures proper processing by clearly identifying the submission as a national phase entry and providing a checklist of required items.

Q: How can companies prepare for potential patent litigation? A: Companies should understand the litigation behavior of PAEs and other entities, and be prepared to defend their patents through strategic planning and legal preparedness.

Sources

  1. PCT Applicant's Guide United States of America - WIPO
  2. PatentSight | LexisNexis Intellectual Property Solutions
  3. Patent Assertion Entity Activity: An FTC Study - FTC
  4. Determining Inventorship for US Patent Applications - Oregon State University
  5. Serco Processes 4 Millionth Patent Application for U.S. Patent and Trademark Office - Serco

More… ↓

⤷  Subscribe

Details for Patent 8,377,690

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen Inc. PROLIA denosumab Injection 125320 June 01, 2010 8,377,690 2016-12-23
Amgen Inc. XGEVA denosumab Injection 125320 November 18, 2010 8,377,690 2016-12-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 8,377,690

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9958674 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 9828426 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 9828424 ⤷  Subscribe
United States of America 8715683 ⤷  Subscribe
United States of America 8569456 ⤷  Subscribe
United States of America 8333963 ⤷  Subscribe
United States of America 8153775 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.